AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01874717
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04120363
Drug: Sesame Oil
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intramuscular injection of 750 mg sesame oil solution
Trial: NCT02368288
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
Trial: NCT00821093
Drug: Salmeterol 50 µg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
Trial: NCT00821093
Drug: Placebo to salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
Trial: NCT01002898
Drug: lopinavir/ritonavir soft gel capsule
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
Trial: NCT01484015
Drug: cefepime hydrochloride
RxNorm normalized name: Cefepime Hydrochloride
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00135226
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00135226
Drug: Omega-3 Ethyl Esters
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135226
Drug: Placebo Omega-3 Ethyl Esters
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00614354
Drug: 99mTc-glucarate solution
RxNorm normalized name: calcium glucarate
DrugBank: 99mTc-glucarate (DB05810)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
Trial: NCT00074607
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year.
Trial: NCT02077374
Drug: IDN-6556
RxNorm normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BID for 28 days
Trial: NCT00072670
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
Trial: NCT01442766
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
Trial: NCT01727193
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
Trial: NCT03434106
Drug: liposic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Trial: NCT03434106
Drug: Tears Naturale Forte
RxNorm normalized name: Tears Naturale Forte
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medication is used to relieve dry, irritated eyes
Trial: NCT04325737
Drug: SEP-363856
RxNorm normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
Trial: NCT01375582
Drug: Liposic EDO
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Drop
Trial: NCT01375582
Drug: OcuFresh Eye Wash
RxNorm normalized name: Sodium Chloride 9 MG/1 ML Ophthalmic Solution [OCUFRESH EYE WASH]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline drop
Trial: NCT03379597
Drug: Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
RxNorm normalized name: Bifidobacterium animalis / Lactobacillus acidophilus Oral Capsule
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifico 840mg Bid
Trial: NCT02618876
Drug: Nalbuphine plus Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of caudal Nalbuphine to the standard Bupivacaine
Trial: NCT02618876
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudal Bupivacaine is the standard of care will be considered as a control
Trial: NCT00753896
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 2.0mcg, once weekly
Trial: NCT01280656
Drug: Conventional Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional interferon according to the standard of care and aligned with the local prescription instructions
Trial: NCT01280656
Drug: Peginterferon Alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
Trial: NCT01280656
Drug: Peginterferon Alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
Trial: NCT01280656
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin according to the standard of care and aligned with the local prescription instructions
Trial: NCT00634348
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
Trial: NCT00634348
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
Trial: NCT02649478
Drug: Fluticasone / Salmeterol
RxNorm normalized name: fluticasone / salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
Trial: NCT03576378
Drug: BrentuximabVedotin (BV)
RxNorm normalized name: Bifidobacterium longum bv. infantis whole
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be treated with 6 cycles of BV-EPEM
Trial: NCT00017680
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 twice a day from Days -2 and -1 as induction therapy
Trial: NCT03245996
Drug: Atenolol Pill
RxNorm normalized name: atenolol Pill
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 or 100 mg of atenolol is administered to subjects in the second part of the study
Trial: NCT03245996
Drug: Nebivolol Pill
RxNorm normalized name: nebivolol Pill
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg of nebivolol is administered to subjects in the second part of the study
Trial: NCT03245996
Drug: Ivabradine Pill
RxNorm normalized name: ivabradine Pill
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
Trial: NCT04422210
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
Trial: NCT04422210
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
Trial: NCT04422210
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
Trial: NCT04422210
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
Trial: NCT03022747
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
Trial: NCT02349802
Drug: Auto-injector with exenatide suspension
RxNorm normalized name: exenatide Auto-Injector
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A flexible study design to accommodate multiple cohorts.
Trial: NCT02349802
Drug: Syringe with exenatide suspension
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A flexible study design to accommodate multiple cohorts.
Trial: NCT00134056
Drug: atrasentan hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00134056
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel given IV and prednisone given orally
Trial: NCT00134056
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel given IV and prednisone given orally
Trial: NCT01923870
Drug: Androxal 25 mg
RxNorm normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00658632
Drug: Rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
Trial: NCT00658632
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Trial: NCT03639194
Drug: ABBV-011
RxNorm normalized name: ABBV-011
DrugBank: ABBV-011 (DB18622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT03639194
Drug: Budigalimab
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT02954276
Drug: Omexa Sublingual Sumatriptan tablet
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg
Trial: NCT01656512
Drug: calcium & vitamin D
RxNorm normalized name: Biotin Plus with Calcium & Vitamin D3 Tablet
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
Trial: NCT00321672
Drug: NGX-4010, 8% capsaicin patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Trial: NCT00321672
Drug: 0.04% capsaicin patch
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Trial: NCT00257556
Drug: Menotrophin
RxNorm normalized name: Menotrophin
DrugBank: Menotropins (DB00032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Trial: NCT00257556
Drug: Follitropin alfa
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
Trial: NCT03760809
Drug: Dexmedetomidine 0.5μg／kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
Trial: NCT03760809
Drug: Dexmedetomidine 1μg／kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
Trial: NCT00455715
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
Trial: NCT01034774
Drug: Placebo (normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
Trial: NCT00003996
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003996
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003996
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02420847
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02420847
Drug: Ixazomib Citrate
RxNorm normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00410150
Drug: Helium-oxygen-driven albuterol nebulizer
RxNorm normalized name: helium / oxygen
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with continuous albuterol nebs with Heliox
Trial: NCT00410150
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with continuous albuterol nebs in oxygen
Trial: NCT02108496
Drug: Intra-Articular Injections with Hyaluronic Acid (HA)
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Trial: NCT04623996
Drug: TP-0184
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral dose
Trial: NCT00401960
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
Trial: NCT02978040
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
Trial: NCT01872260
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg/day
Trial: NCT02978040
Drug: Tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
Trial: NCT02338466
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
Trial: NCT02338466
Drug: tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg).
Trial: NCT03173365
Drug: Brimonidine Tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
Trial: NCT02415062
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 23mg/day for 24 weeks versus 10mg/day for 24 weeks
Trial: NCT02978040
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
Trial: NCT01798537
Drug: Neomycin Colistin Nystatin Vancomycin
RxNorm normalized name: colistin / hydrocortisone / neomycin / thonzonium
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participating study arm patients will receive SDD from admission to discharge
Trial: NCT01490047
Drug: Recombinant human TNF-α
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
Trial: NCT01490047
Drug: Caelyx
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
Trial: NCT01110668
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00178269
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no